This is consistent with previous findings that IFITM restricts SARS-CoV infection at a late stage in the endocytic pathway, most likely by inhibiting viral envelope protein-induced membrane hemifusion [43,58]. This evidence concerns the gene ERVW-1 and severe acute respiratory syndrome.